Article

Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

Diabetes, Obesity and Metabolism
DOI: 10.1111/dom.14978
4Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Author supplied keywords

Cite

CITATION STYLE

APA

Koshino, A., Oshima, M., Arnott, C., Fletcher, R. A., Bakris, G. L., Jardine, M., … Neuen, B. L. (2023, May 1). Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes, Obesity and Metabolism. John Wiley and Sons Inc. https://doi.org/10.1111/dom.14978

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free